|

tabelecleucel Clinical Trials

1 actively recruiting trial across 1 location

No change since May 2026

Also known as: ATA129, EBV-CTL, EBV-CTLs, Ebvallo®, tab-cel®

Pipeline

Phase 3: 1

Top Sponsors

  • Pierre Fabre Medicament1

Indications

  • Liver Disease1
  • Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)1
  • Heart Disease1
  • Allogeneic Hematopoietic Cell Transplant1
  • Lymphoproliferative Disorders1

Duarte, California1 trial

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

City of Hope (Adults and Pediatrics)

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.